Mounjaro Injection UK is a practical guide to the once-weekly Mounjaro (tirzepatide) injection: what the UK licence covers, how the dose is built up, how to use and store the KwikPen, and which side effects to expect.
Who is it for?
People in the UK who have been prescribed Mounjaro, are discussing it with a prescriber, or want to understand it first, and anyone helping them. The pages stay with practical detail: injection days, injection sites, storage, missed doses and the first weeks on the starter dose.
What does it cover?
- The overview: what the injection is, how it works and who the UK label is for.
- Doses and strengths: the six pen strengths from 2.5mg to 15mg and the four-week step-up.
- Using and storing the pen: sites and rotation, fridge storage, the 30-day in-use window and sharps disposal.
- Side effects: trial frequencies, serious risks and who should not take it.
- How it was developed: the dual GIP/GLP-1 science, the SURPASS and SURMOUNT trials and the approvals.
- The FAQ, plus guides to single practical questions.
Where do the numbers come from?
Doses and storage limits come from the UK Summary of Product Characteristics and the patient information leaflet for the KwikPen, published on the electronic Medicines Compendium. Side-effect frequencies and trial results come from the published SURMOUNT papers, and licensing and NHS access from the MHRA, NICE and NHS England. The main pages list their references, and every page shows when it was published, reviewed or last updated.
Is it connected to Eli Lilly?
No. The site is written by the Mounjaro Injection UK editorial team and is independent of Eli Lilly and Company, with no affiliation to, endorsement from or other connection with the company. Nothing is sold, supplied, prescribed or dispensed here, and there are no links to any provider. Manufacturer and regulator pages are cited only as sources for what the label says.
Can it replace advice from a prescriber?
No. Mounjaro is a prescription-only medicine, and whether it is suitable for you is a decision for a qualified prescriber after a proper consultation. Nothing here is medical advice or an encouragement to use any medicine, and it does not replace the leaflet that comes with your pen. Report suspected side effects through the MHRA Yellow Card scheme and speak to your GP or pharmacist.